Sortiert nach PI

Publikationen - sortiert nach Principle Investigator

• Zifko U, Guendling K, Seet R, Kasper S (2024) Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care Front. Pharmacol., 15: 1338235
  | Weblink |
• Bartova L, Fugger G, Dold M, Kautzky A, Bairhuber I, Kloimstein P, Fanelli G, Zanardi R, Weidenauer A, Rujescu D, Souery D, Mendlewicz J, Zohar J, Montgomery S, Fabbri C, Serretti A, Kasper S (2024) The clinical perspective on late-onset depression in European real-world treatment settings Int. J. Neuropsychopharmacol., 84: 59-68
  | Weblink |
• Kasper S, Volz H, Möller H, Schläfke S, Klement S, Anghelescu I, Seifritz E (2024) Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial Eur Arch Psychiatry Clin Neurosci,
  | Weblink |
• Oliva V, Martone A, Fanelli G, Domschke K, Minelli A, Gennarelli M, Martini P, Bortolomasi M, Maron E, Squassina A, Pisanu C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Baune B, Serretti A, Fabbri C, Potier M, van Westrhenen R, Rybakowski F, Mehta D, Dierssen M, Janzing J, Liò P (2024) Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression Neuroscience Applied, 3: 103937
  | Weblink |
• Kadriu B, Deng Z, Kraus C, Johnston J, Fijtman A, Henter I, Kasper S, Zarate C (2024) The impact of body mass index on the clinical features of bipolar disorder: A STEP-BD study Bipolar Disorders, 26: 160-175
  | Weblink |

• Lochmann van Bennekom M, IntHout J, Gijsman H, Akdede B, Yağcıoğlu A, Barnes T, Galling B, Gueorguieva R, Kasper S, Kreinin A, Nielsen J, Nielsen R, Remington G, Repo-Tiihonen E, Schmidt-Kraepelin C, Shafti S, Xiao L, Correll C, Verkes R (2024) Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data Schizophr Res, 272: 1-11
  | Weblink |

• Spies M, Silberbauer L, Kasper S (2023) Letter to the editor refers to “Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression” Decision making in treatment resistant depression: appeal for an individualized approach. N Engl J Med, 389 (10): 960
  | Weblink |
• Kasper S, Eckert A, Möller H, Volz H, Seifritz E (2023) Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan Int J Psychiatry Clin Pract, 27 (3): 285-291
  | Weblink |
• Wegener T, Edwards D, Kasper S (2023) The potential role of Rhodiola rosea L. extract WS® 1375 for patients with post-COVID-19 fatigue hb TIMES Schw Aerztej, 8 (1): 56-61
  | Weblink |
• Buchmayer F, Kasper S (2023) Overcoming the myths of esketamine administration: different and not difficult Front Psychiatry, 14
  | Weblink |
• Kasper S (2023) Cheers and a thank-you note from the founding chief-editor Int J Psychiatry Clin Pract, 27 (4): 319-322
  | Weblink |
• McIntyre R, Alsuwaidan M, Baune B, Berk M, Demyttenaere K, Goldberg J, Gorwood P, Ho R, Kasper S, Kennedy S, Ly‐Uson J, Mansur R, McAllister‐Williams R, Murrough J, Nemeroff C, Nierenberg A, Rosenblat J, Sanacora G, Schatzberg A, Shelton R, Stahl S, Trivedi M, Vieta E, Vinberg M, Williams N, Young A, Maj M (2023) Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions World Psychiatry, 22 (3): 394-412
  | Weblink |
• Kautzky A, Bartova L, Fugger G, Dold M, Souery D, Montgomery S, Zohar J, Mendlewicz J, Fabbri C, Serretti A, Rujescu D, Kasper S (2023) Age as a moderating factor of treatment resistance in depression Eur Psychiatry, 66: ahead of print
  | Weblink |
• Dold M, Bartova L, Volz H, Seifritz E, Möller H, Schläfke S, Kasper S (2023) Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials Eur Arch Psychiatry Clin Neurosci, 273 (7): 1615-1628
  | Weblink |
• Stöhrmann P, Godbersen G, Reed M, Unterholzner J, Klöbl M, Baldinger-Melich P, Vanicek T, Hahn A, Lanzenberger R, Kasper S, Kranz G (2023) Effects of bilateral sequential theta-burst stimulation on functional connectivity in treatment-resistant depression: first results J Affect Disord, 324: 660-669
  | Weblink |
• Murgaš M, Unterholzner J, Stöhrmann P, Philippe C, Godbersen G, Nics L, Reed M, Vraka C, Vanicek T, Wadsak W, Kranz G, Hahn A, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Baldinger-Melich P (2023) Effects of bilateral sequential theta-burst stimulation on 5-HT1A receptors in the dorsolateral prefrontal cortex in treatment-resistant depression: a proof-of-concept trial Transl Psychiat, 13 (1)
  | Weblink |
• Kraus C, Kautzky A, Watzal V, Gramser A, Kadriu B, Deng Z, Bartova L, Zarate C, Lanzenberger R, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fanelli G, Serretti A, Kasper S (2023) Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database J Affect Disord, 335: 349-357
  | Weblink |
• Bartova L, Fugger G, Dold M, Kautzky A, Fanelli G, Zanardi R, Albani D, Weidenauer A, Rujescu D, Souery D, Mendlewicz J, Montgomery S, Zohar J, Fabbri C, Serretti A, Kasper S (2023) Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder J Affect Disord, 332: 105-114
  | Weblink |
• Kasper S (2023) Fluch oder Segen von Benzodiazepinen: neu bewertet Jatros Neurologie & Psychiatrie , : 5
• Kasper S (2023) Evidenzbasis pflanzlicher Arzneimittel in der Psychopharmakotherapie Psychopharmakotherap, 30: 11-20
• Oliva V, Fanelli G, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Fabbri C, Serretti A (2023) Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns J Affect Disord, 320: 534-543
  | Weblink |

• Pallanti S, Zohar J, Kasper S, Möller H, Hollander E (2023) Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach Psychiat Gen, 170: 65-72
  | Weblink |
• Bartova L, Lanzenberger R, Rujescu D, Kasper S (2023) Reply to: “The serotonin theory of depression: a systematic umbrella review of the evidence” published by Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA in Molecular Psychiatry (2022 Jul 20. doi: 10.1038/s41380-022-01661-0) Mol Psychiatry, 28 (8): 3153-3154
  | Weblink |
• Himmerich H, Lewis Y, Conti C, Mutwalli H, Karwautz A, Sjögren J, Uribe Isaza M, Tyszkiewicz-Nwafor M, Aigner M, McElroy S, Treasure J, Kasper S, Bailer U, Bulik C, Conti C, Zwaan M, Favaro A, Fernandez-Aranda F, Fetissov S, Hilbert A, Himmerich H, Wijbrand Hoek H, Kan C, Karpenko O, Karwautz A, Kasper S, Kaye W, Lewis Y, McElroy S, Mitchell J, Monteleone P, Mörkl S, Müller D, Mutwalli H, Nazar B, Papežová H, Sjögren J, Steiger H, Stein D, Szabo C, Tyszkiewicz-Nwafor M, Voderholzer U, Uribe Isaza M, Wade T, Wranik W, Yoshiuchi K, (2023) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders World J Biol Psychiatry, 24: 643-706
  | Weblink |
• Bartova L, Dold M, Fugger G, Weidenauer A, Rujescu D, Kasper S (2023) Silexan for treatment of anxiety and depression in the context of COVID-19 Eur Neuropsychopharmacol, 70: 47-48
  | Weblink |

• Inada K, Yamawaki S, Kanba S, Shinozaki G, Kasper S (2023) General Principles of Pharmacologic Therapy. In: Springer Verlag, Springer Verlag Heidelberg, New York Springer Verlag, Heidelberg, New York: ahead of print
  | Weblink |

• Seifritz E, Kasper S, Möller H, Volz H, Müller W, Eckert A, Hatzinger M (2022) Effect of anxiolytic drug silexan on sleep – a narrative review World J Biol Psychiatry, 23 (7): 493-500
  | Weblink |
• Pain O,..,the GSRD Consortium, the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, McIntosh AM, Lewis CM (2022) Identifying the Common Genetic Basis of Antidepressant Response Biological Psychiatry GOS, 2 (2): 115-126
  | Weblink |
• Panariello F, Kasper S, Zohar J, Souery D, Montgomery S, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Serretti A, Fabbri C (2022) Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting World J Biol Psychiatry, 24 (5): 439-448
  | Weblink |
• Roca M, Bonelli A, Cattaneo A, Comandini A, Di Dato G, Heiman F, Pegoraro V, Kasper S, Volz H, Palao D (2022) Factors associated with sick leave duration in patients suffering from major depressive disorder initiating antidepressant treatment: a real-world evidence study in Germany and Spain Int J Psychiatry Clin Pract, 27 (1): 59-68
  | Weblink |
• Silberbauer L, Rischka L, Vraka C, Hartmann A, Godbersen G, Philippe C, Pacher D, Nics L, Klöbl M, Unterholzner J, Stimpfl T, Wadsak W, Hahn A, Hacker M, Rujescu D, Kasper S, Lanzenberger R, Gryglewski G (2022) ABCB1 variants and sex affect serotonin transporter occupancy in the brain Mol Psychiatry, 27 (11): 4502-4509
  | Weblink |
• Bandelow B, Allgulander C, Baldwin D, Costa D, Denys D, Dilbaz N, Domschke K, Eriksson E, Fineberg N, Hättenschwiler J, Hollander E, Kaiya H, Karavaeva T, Kasper S, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Möller H, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J (2022) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders World J Biol Psychiatry, 24 (2): 79-117
  | Weblink |
• Bandelow B, Allgulander C, Baldwin D, Costa D, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller H, Eriksson E, Fineberg N, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J (2022) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD World J Biol Psychiatry, 24 (2): 118-134
  | Weblink |
• Ludwig B, Carlberg L, Kienesberger K, Swoboda P, Swoboda M, Bernegger A, Koller R, Inaner M, Fuxjäger M, Zotter M, Schmelzle N, Senft B, Meisner L, Fischer-Hansal D, Huber J, Schoenthaler S, Kapusta N, Haslacher H, Aigner M, Weinhaeusel A, Kasper S, Schosser A (2022) Oxytocin receptor gene methylation as a molecular marker for severity of depressive symptoms in affective disorder patients BMC Psychiatry, 22 (1): 1-8
  | Weblink |
• L. Bartova, G. Fugger, M. Dold, S. Kasper (2022) Therapieoptionen bei Angsterkrankungen unter Berücksichtigung der Phyto- Psychopharmakotherapie Journal für Neurologie, Neurochirurgie und Psychiatrie, 23: 124-130
• Vanicek T, Reed M, Seiger R, Godbersen G, Klöbl M, Unterholzner J, Spurny-Dworak B, Gryglewski G, Handschuh P, Schmidt C, Kraus C, Stimpfl T, Rupprecht R, Kasper S, Lanzenberger R (2022) Increased left dorsolateral prefrontal cortex density following escitalopram intake during relearning: a randomized, placebo-controlled trial in healthy humans Ther Adv Psychopharmacol, 12: 1-15
  | Weblink |
• Zhang B, Stöhrmann P, Godbersen G, Unterholzner J, Kasper S, Kranz G, Lanzenberger R (2022) Normal component of TMS-induced electric field is correlated with depressive symptom relief in treatment-resistant depression Brain Stimul, 15 (5): 1318-1320
  | Weblink |
• Bartova L, Fugger G, Dold M, Kautzky A, Rujescu D, Kasper S (2022) Psychotherapy’s Role for Treatment-Resistant Depression? Am J Psychiatry, 179 (9): 687-687
  | Weblink |
• Spurny-Dworak B, Godbersen GM, Reed MB, Unterholzner J, Vanicek T, Baldinger-Melich P, Hahn A, Kranz GS, Bogner W, Lanzenberger R, Kasper S (2022) The impact of theta-burst stimulation on cortical GABA and glutamate in treatment-resistant depression: A surface-based MRSI analysis approach. Front Mol Neurosci, : 913274
  | Weblink |
• Bartova L, Dold M, Volz HP, Seifritz E, Möller HJ, Kasper S (2022) Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders – randomized, placebo-controlled trials revisited. Eur Arch Psychiatry Clin Neurosci,
  | Weblink |
• Fanelli G, Domschke K, Minelli A, Gennarelli M, Martini P, Bortolomasi M, Maron E, Squassina A, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Baune BT, European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Thematic Working Group, Serretti A, Fabbri C (2022) A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. Eur Neuropsychopharmacol, 55: 86-95
  | Weblink |
• Oliva V, Fanelli G, Kasper S; Zohar J, Souery D; Montgomery S, Albani D; Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Kas M, De Ronchi D, Fabbri C, Serretti A (2022) Social withdrawal as a trans-diagnostic predictor of short-term remission. A meta-analysis of five clinical cohorts. Int Clin Psychopharmacol, 37: 38 – 45
  | Weblink |
• Fugger G, Bartova L, Dold M, Fabbri C, Fanelli G, Zanardi R, Kautzky A, Zohar J, Souery D, Mendlewicz J, Montgomery S, Rujescu D, Serretti A, Kasper S (2022) Evidence on Sociodemographic and Clinical Correlates of Antidepressant Combination or Augmentation with Second-Generation Antipsychotics in Major Depressive Disorder. Prog in Neuropsychopharmaco & Biolog. Psychiatry , 114: 110480
  | Weblink |
• Fugger G, Bartova L, Fabbri C, Fanelli G, Zanardi R, Dold M, Kautzky A, Rujescu D, Souery D, Mendlewicz J, Zohar J, Montgomery S, Serretti A, Kasper S (2022) The Sociodemographic and Clinical Phenotype of European Patients with Major Depressive Disorder Undergoing first-line Antidepressant Treatment with NaSSAs J Affect Disord, : 225-234
  | Weblink |
• Fugger G, Bartova L, Fabbri C, Fanelli G, Dold M, Swoboda MMM, Kautzky A, Zohar J, Souery D, Mendlewicz J, Montgomery S, Rujescu D, Serretti A, Kasper S (2022) The Sociodemographic and Clinical Profile of Patients with Major Depressive Disorder Receiving SSRIs as First-line Antidepressant Treatment in European Countries. Eur Arch Psychiatry Clin Neurosci,
  | Weblink |
• de Bardeci M, Greil W, Stassen H, Willms J, Köberle U, Bridler R, Hasler G, Kasper S, Rüther E, Bleich S, Toto S, Grohmann R, Seifert J (2022) Dear Doctor Letters regarding Citalopram and Escitalopram: Guidelines vs real world data. Eur Arch Psychiatry Clin Neurosci,
  | Weblink |
• Bartova L, Fugger G, Dold M, Kautzky A, Swoboda MMM, Rujescu D, Zohar J, Souery D, Mendlewicz J, Montgomery S, Fabbri C, Serretti A, Kasper S (2022) The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. Int. J. Neuropsychopharmacol., 25: 118-127
  | Weblink |
• Calabrò M, Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Serretti A, Crisafulli C (2022) Metabolizing status of CYP2C19 in response and side effects to medications for depression: results from a naturalistic study. Eur Neuropsychopharmacol, 56: 100-111
  | Weblink |
• Kasper S (2022) Initiating Antidepressant Medication: What is the Most Important Factor? Adv in Therapy, : S5-S12,
  | Weblink |
• Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge J, McIntyre RS, Akhondzadeh S, Benedetti F, Caneo C, Cramer H, Cribb L, de Manincor M, Dean O, Deslandes AC, Freeman MP, Gangadhar B, Harvey BH, Kasper S, Lake J, Lopresti A, Lu L, Metri NJ, Mischoulon D, Ng C, Nishi D, Rahimi R, Seedat S, Sincliar J, Su KP, Zhang ZJ, Berk M (2022) Clinician Guidelines for the Treatment of Psychiatric Disorders with Nutraceuticals and Phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry, 23: 424-455
  | Weblink |
• Volz H, Bartečků E, Bartova L, Bessa J, De Berardis D, Dragasek J, Kozhuharov H, Ladea M, Lazáry J, Roca M, Usov G, Wichniak A, Godman B, Kasper S (2022) Sick leave duration as a potential marker of functionality and disease severity in depression Int J Psychiatry Clin Pract, 26 (4): 406-416
  | Weblink |
• Komorowski A, Murgas M, Vidal R, Singh A, Gryglewski G, Kasper S, Wiltfang J, Lanzenberger R, Goya-Maldonado R (2022) Regional gene expression patterns are associated with task-specific brain activation during reward and emotion processing measured with functional MRI Human Brain Mapping, 43: 5266-5280
  | Weblink |
• Fanelli G, Sokolowski M, Wasserman D, European College of Neuropsychopopharmacology (ECNP) Network on Suicide Research and Prevention, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Serretti A, Fabbri C (2022) Polygenic risk scores for neuropsychiatric, inflammatory, and cardio-metabolic traits highlight possible genetic overlap with suicide attempt and treatment-emergent suicidal ideation Am. J. Med. Genet. B Neuropsychiatr. Genet. , : 74-85
  | Weblink |
• Pain O, Hodgson K, Trubetskoy V, Ripke S, Marshe VS, Adams MJ, Byrne EM, Campos AI, Carillo-Roa T, Cattaneo A, Als TD, Souery D, Dernovsek MZ, Fabbri C, Hayward C, Jenigsberg N, Hauser J, Kennedy JL, Lenze EJ, Lewis G, Müller DJ, Martin NG, Mulsant BH, Mors O, Perroud N, Porteous DJ, Renteria ME, Reynolds III CF, Rietschel M, Uher R, Wigmore EM, Maier W, Wray NR, Aitchison KJ, Arolt V, Baune BT, Biernacka JM, Bondolfi G, Domschke K, Kato M, Li QS, Liu YL, Serretti A, Tsai SJ, Turecki G, Weinshilboum R, the GSRD Consortium, the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, McIntosh AM, Lewis CM (2022) Identifying the common genetic basis of antidepressant response. Biol Psychiatry, 2: 115-126
  | Weblink |
• Generoso M, Taiar I, Cordeiro Q, Shiozawa P, Kasper S (2022) Cariprazine for treating psychosis: an updated meta-analysis Int J Psychiatry Clin Pract, 27 (1): 107-109
  | Weblink |
• Friedrich ME, Grohmann R, Rabl U, Winkler D, Konstantinidis A, Engel R, Seifert J, Toto S, Stübner S, Frey R, Kasper S (2022) Incidence of drug-induced delirium during treatment with antidepressants or antipsychotics – a drug surveillance report of German-speaking countries between 1993 and 2016. Int. J. Neuropsychopharmacol., 25: 556-566
  | Weblink |
• Vanicek T, Unterholzner J, Lanzenberger R, Naderi-Heiden A, Kasper S, Praschak-Rieder N (2022) Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder World J Biol Psychiatry, 23 (9): 715-718
  | Weblink |

• Kasper S (2022) Rasch wirkende Antidepressiva bei Major Depression und therapieresistenter Depression Jatros Neurologie & Psychiatrie , 5: 38
• Kasper S, Sachs G, Erfurth A, Rujescu D, Bach M, Baldinger-Melich P, Bartova L, Conca A, Dold M, Frey R, Goessler R, Hausmann A, Lan-zenberger R, Lehofer M, Marksteiner J, Naderi-Heiden A, Plener P, Praschak-Rieder N, Rados C, Schosser A, Sperner-Unterweger B, Spies M, Winkler D (2022) Angststörungen Psychopharmakotherapie Jatros Neurologie & Psychiatrie ,
• Möller HJ, Kasper S (2022) Serotonin-Theorie der Depression in Umbrella-Review nicht bestätigt? Psychopharmakotherap, 29: 187-189
• Kasper S (2022) Suizidalität: Von einer psychiatrischen zu einer juristischen Sichtweise? Jatros Neurologie & Psychiatrie , : 24-25
• Kasper S. (2022) Suizidalität: Von einer psychiatrischen zu einer juristischen Sichtweise? Journal für Neurologie, Neurochirurgie und Psychiatrie, 23: 5-6
• Kasper S, Erfurth A, Sachs G, Aichhorn W, Bartova L, Bengesser S, Buchmayer F, Deisenhammer E, Di Pauli J, Dold M, Falkai P, Frey R, Glück K, Hofer A, Holsboer-Trachsler E, Kautzky A, Konstantinidis A, Kraus C, Lehofer M, Marksteiner J, Mitschek M, Mörkl S, Oberlerchner H, Plener P, Psota G, Rados C, Rainer M, Schosser A, Seifritz E, Silberbauer C, Winkler D, Wunsch C, Zwanzger P (2022) Treatment-resistant Depression: Diagnosis and Treatment, Konsensus-Statement Jatros Neurologie & Psychiatrie , : 1-31
• Fugger G, Bartova L, Dold M, Kasper S (2022) Die therapieresistente Depression (TRD) – Herausforderungen und praktisches Management. psychopraxis. neuropraxis, : 49 – 54
  | Weblink |
• Kasper S (2022) Is treatment-resistant depression really resistant? Eur Neuropsychopharmacol, : 44–46
  | Weblink |

• Mitschek M, Vanicek T, Unterholzner J, Kraus C, Weidenauer A, Naderi-Heiden A, Frey R, Silberbauer L, Gryglewski G, Papageorgiou K, Winkler D, Dold M, Kasper S, Praschak-Rieder N, Bartova L (2021) How to prevent and manage hyperammonemic encephalopathies in valproate therapy J Affect Disord, 5: 100186
  | Weblink |
• Volz H, Saliger J, Kasper S, Möller H, Seifritz E (2021) Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey Int J Psychiatry Clin Pract,
  | Weblink |
• Bartova L, Dold M, Fugger G, Kautzky A, Mitschek M, Weidenauer A, Hienert M, Frey R, Mandelli L, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S (2021) Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression Depress Anxiety,
  | Weblink |
• Rischka L, Godbersen G, Pichler V, Michenthaler P, Klug S, Klöbl M, Ritter V, Wadsak W, Hacker M, Kasper S, Lanzenberger R, Hahn A (2021) Reliability of task-specific neuronal activation assessed with functional PET, ASL and BOLD imaging Cereb Blood Flow Metab, : 0271678X2110205
  | Weblink |
• Ludwig B, Carlberg L, Kienesberger K, Swoboda P, Mitschek M, Bernegger A, Koller R, Inaner M, Senft B, Meisner L, Fischer-Hansal D, Affenzeller A, Huber J, Schoenthaler S, Kapusta N, Haslacher H, Aigner M, Weinhaeusel A, Kasper S, Schosser A (2021) Monoamino Oxidase a Gene Single-Nucleotide Polymorphisms and Methylation Status and the Risk of Violent Suicide Attempts in Affective Disorder Patients Front Psychiatry, 12
  | Weblink |
• Bartova L, Fugger G, Dold M, Swoboda M, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S (2021) Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression J Psychiatr Res, 141: 167-175
  | Weblink |
• Milenkovic I, Bartova L, Papageorgiou K, Kasper S, Traub-Weidinger T, Winkler D (2021) Case Report: Bupropion Reduces the [123I]FP-CIT Binding to Striatal Dopamine Transporter Front Psychiatry, 12: 631357
  | Weblink |
• Höflich A, Kraus C, Pfeiffer R, Seiger R, Rujescu D, Zarate C, Kasper S, Winkler D, Lanzenberger R (2021) Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial Transl Psychiat, 11 (1): 200
  | Weblink |
• Dold M, Bartova L, Fugger G, Kautzky A, Mitschek M, Fabbri C, Montgomery S, Zohar J, Souery D, Mendlewicz J, Serretti A, Kasper S (2021) Melancholic features in major depression – a European multicenter study Prog Neuropsychopharmacol Biol Psychiatry, 110: 110285
  | Weblink |
• McIntyre R, Rosenblat J, Nemeroff C, Sanacora G, Murrough J, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu D, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee J, Lee Y, Lui L, Mansur R, Papakostas G, Subramaniapillai M, Thase M, Vieta E, Young A, Zarate C, Stahl S (2021) Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Am J Psychiatry, 178 (5): 383-399
  | Weblink |
• von Känel R, Kasper S, Bondolfi G, Holsboer‐Trachsler E, Hättenschwiler J, Hatzinger M, Imboden C, Heitlinger E, Seifritz E (2021) Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta‐analysis Brain and Behavior, 11 (4): e01997
  | Weblink |
• Bartova L, Dold M, Fugger G, Kautzky A, Mitschek M, Weidenauer A, Handschuh P, Frey R, Mandelli L, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S (2021) The Role of Relationship Status in Major Depressive Disorder Results of the European Group for the Study of Resistant Depression J Affect Disord, 286: 149-157
  | Weblink |
• Seiger R, Gryglewski G, Klöbl M, Kautzky A, Godbersen G, Rischka L, Vanicek T, Hienert M, Unterholzner J, Silberbauer L, Michenthaler P, Handschuh P, Hahn A, Kasper S, Lanzenberger R (2021) The influence of acute SSRI administration on white matter microstructure in patients suffering from major depressive disorder and healthy controls Int J Neuropsychopharmacol, 24 (7): 542-550
  | Weblink |
• Sarris J, Marx W, Ashton M, Ng C, Galvao-Coelho N, Ayati Z, Zhang Z, Kasper S, Ravindran A, Harvey B, Lopresti A, Mischoulon D, Amsterdam J, Yatham L, Berk M (2021) Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d’essais randomisés contrôlés Can J Psychiatry, 6: 849-862
  | Weblink |
• McAllister-Williams R, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, Hopwood M, Javed A, Kasper S, Malhi G, Soares J, Vieta E, Young A, Papadopoulos A, Rush A (2021) Reconceptualising treatment-resistant depression as difficult-to-treat depression Lancet Psychiatry, 8 (1): 14-15
  | Weblink |
• Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Serretti A, Lewis C (2021) Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression J Affect Disord, 279: 722-729
  | Weblink |
• Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Riva M, Lewis C, Serretti A (2021) Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study Prog Neuropsychopharmacol Biol Psychiatry, 104: 110050
  | Weblink |
• Fanelli G, Benedetti F, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Serretti A, Fabbri C (2021) Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder Prog Neuropsychopharmacol Biol Psychiatry, : 110170
  | Weblink |
• Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, Hough D, Drevets WC, Manji H, Canuso CM (2021) Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) Int J Neuropsychopharmacol, 24(1): 22-31
  | Weblink |
• Kautzky A, Möller H, Dold M, Bartova L, Seemüller F, Laux G, Riedel M, Gaebel W, Kasper S (2021) Combining machine learning algorithms for prediction of antidepressant treatment response Acta Psychiatr Scand, 143 (1): 36-49
  | Weblink |
• Möller H, Volz H, Seifritz E, Müller H, Kenntner-Mabiala R, Kaussner Y, Schoch S, Kasper S (2021) Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers J Psychiatr Res, 136: 543-551
  | Weblink |

• Cinquina V, Weidenauer A, Kasper S, Harkany T (2021) Cannabinoids in the brain: their mechanism of action in relation to neuropsychiatric disorders Jatros Neurologie & Psychiatrie , 6: 35-38
• Kasper S, Erfurth A, Sachs G, Aichhorn W, Bartova L, Bengesser S, Buchmayer F, Deisenhammer E, Di Pauli J, Dold M, Falkai P, Frey R, Glück K, Hofer A, Holsboer-Trachsler E, Kautzky A, Konstantinidis A, Kraus C, Lehofer M, Marksteiner J, Mitschek M, Mörkl S, Oberlerchner H, Plener P, Psota G, Rados C, Rainer M, Schosser A, Seifritz E, Silberbauer C, Winkler D, Wunsch C, Zwanzger P (2021) Therapieresistente Depression: Diagnose und Behandlung, Konsensus-Statement Jatros Neurologie & Psychiatrie , Sonderheft 03/2021: 1-32
• Kasper S (2021) Neue Behandlungsperspektiven bei der sog. behandlungsresistenten Depression (TRD) Journal für Neurologie, Neurochirurgie und Psychiatrie, 1: 3-5
  | Weblink |
• Calabrò M, Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Colombo R, De Ronchi D, Serretti A, Crisafulli C (2021) Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression Curr Med Chem, 28 (22): 4296-4320
  | Weblink |
• Dodd S, Bauer M, Carvalho A, Eyre H, Fava M, Kasper S, Kennedy S, Khoo J, Lopez Jaramillo C, Malhi G, McIntyre R, Mitchell P, Castro A, Ratheesh A, Severus E, Suppes T, Trivedi M, Thase M, Yatham L, Young A, Berk M (2021) A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? World J Biol Psychiatry, 22 (7): 483-494
  | Weblink |
• Kasper S, Cubała W, Fagiolini A, Ramos-Quiroga J, Souery D, Young A (2021) Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance World J Biol Psychiatry,
  | Weblink |

• Sachs G, Kasper S, Anditsch M, Erfurth A, Lehofer M, Marksteiner J, Rados C, Rujescu D, Sperner-Unterweger B (2021) Was in der Praxis zählt. Diagnostik und Therapie der generalisierten Angststörung. In: , Jatros Neurologie & Psychiatrie Universimed: 2-6
• Dajić I, Praschak-Rieder N, Lanzenberger R, Spindelegger C, Kasper S, Willeit M (2021) Neuroimaging in Seasons and Winter Depression. In: Rudi A.J.O. Dierckx, Andreas Otte, Erik F. J. de Vries, Aren van Waarde, Iris E. Sommer, PET and SPECT in Psychiatry, Vol.2 Springer International Publishing: 245-259
  | Weblink |

• Seifritz E, Möller H, Volz H, Müller W, Hopyan T, Wacker A, Schläfke S, Kasper S (2020) No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial Int J Neuropsychopharmacol, 24 (3): 171-180
  | Weblink |
• Kraus C, Kadriu B, Lanzenberger R, Zarate C, Kasper S (2020) Prognosis and Improved Outcomes in Major Depression: A Review Focus, 18 (2): 220-235
  | Weblink |
• Kraus C, Hahn A, Sigurdardottir H, Spurny B, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R (2020) Brain glucose uptake during transcranial direct current stimulation measured with functional [18F]FDG-PET Brain Imaging Behav, 14 (2): 477-484
  | Weblink |
• Pjrek E, Friedrich M, Cambioli L, Dold M, Jäger F, Komorowski A, Lanzenberger R, Kasper S, Winkler D (2020) The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials Psychother Psychosom, 89 (1): 17-24
  | Weblink |
• Kasper S, Möller H, Engberg G, Eriksson E, Hökfelt T (2020) Torgny Svensson, a superb mind and an inspiring colleague Int J Neuropsychopharmacol, 23 (8): 543-544
  | Weblink |
• Komorowski A, Weidenauer A, Murgaš M, Sauerzopf U, Wadsak W, Mitterhauser M, Bauer M, Hacker M, Praschak-Rieder N, Kasper S, Lanzenberger R, Willeit M (2020) Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain Neuroimage, 223: 117270
  | Weblink |
• Dold M, Bartova L, Kasper S (2020) Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment Int J Neuropsychopharmacol, 23 (7): 440-445
  | Weblink |
• Fugger G, Dold M, Bartova L, Mitschek M, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Fabbri C, Frey R, Kasper S (2020) Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression Int J Neuropsychopharmacol, 23 (9): 571-577
  | Weblink |
• Unterholzner J, Gryglewski G, Philippe C, Seiger R, Pichler V, Godbersen G, Berroterán-Infante N, Murgaš M, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R (2020) Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data Cereb. Cortex, 30 (6): 3771-3780
  | Weblink |
• Kautzky A, Vanicek T, Philippe C, Kranz G, Wadsak W, Mitterhauser M, Hartmann A, Hahn A, Hacker M, Rujescu D, Kasper S, Lanzenberger R (2020) Machine learning classification of ADHD and HC by multimodal serotonergic data Transl Psychiat, 10: 104
  | Weblink |
• Silberbauer L, Bartova L, Papageorgiou K, Lanzenberger R, Kasper S, Winkler D (2020) Oral Ketamine as a Treatment Option in Patients With Treatment Resistant Depression and Comorbid Arterial Hypertension J Clin Psychopharmacol, 40 (4): 418-420
• Hahn A, Breakspear M, Rischka L, Wadsak W, Godbersen G, Pichler V, Michenthaler P, Vanicek T, Hacker M, Kasper S, Lanzenberger R, Cocchi L (2020) Reconfiguration of functional brain networks and metabolic cost converge during task performance eLife, 9: e52443
  | Weblink |
• Calabrò M, Porcelli S, Crisafulli C, Albani D, Kasper S, Zohar J, Souery D, Montgomery S, Mantovani V, Mendlewicz J, Bonassi S, Vieta E, Frustaci A, Ducci G, Landi S, Boccia S, Bellomo A, Di Nicola M, Janiri L, Colombo R, Benedetti F, Mandelli L, Fabbri C, Serretti A (2020) Genetic variants associated with psychotic symptoms across psychiatric disorders Neurosci Lett, 720: 134754
  | Weblink |
• Spurny B, Seiger R, Moser P, Vanicek T, Reed M, Heckova E, Michenthaler P, Basaran A, Gryglewski G, Klöbl M, Trattnig S, Kasper S, Bogner W, Lanzenberger R (2020) Hippocampal GABA levels correlate with retrieval performance in an associative learning paradigm Neuroimage, 204: 116244
  | Weblink |
• Porcelli S, Kasper S, Zohar J, Souery D, Montgomery S, Ferentinos P, Rujescu D, Mendlewicz J, Merlo Pich E, Pollentier S, Penninx B, Serretti A (2020) Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples Prog Neuropsychopharmacol Biol Psychiatry, 99: 109835
  | Weblink |
• Fagiolini A, Albert U, Ferrando L, Herman E, Muntean C, Pálová E, Cattaneo A, Comandini A, Di Dato G, Di Loreto G, Olivieri L, Salvatori E, Tongiani S, Kasper S (2020) A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder Int Clin Psychopharmacol, 35 (3): 137-146
  | Weblink |
• Dold M, Bartova L, Fugger G, Mitschek M, Kautzky A, Frey R, Montgomery S, Zohar J, Mendlewicz J, Souery D, Fabbri C, Serretti A, Kasper S (2020) Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study Eur Neuropsychopharmacol, 41: 70-80
  | Weblink |
• Klöbl M, Gryglewski G, Rischka L, Godbersen G, Unterholzner J, Reed M, Michenthaler P, Vanicek T, Winkler-Pjrek E, Hahn A, Kasper S, Lanzenberger R (2020) Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge Front Comput Neurosci, 14: 554186
  | Weblink |
• Wajs E, Aluisio L, Holder R, Daly E, Lane R, Lim P, George J, Morrison R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Grunfeld J, Jeon H, Wilkinson S, Drevets W, Singh J (2020) Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression J Clin Psychiatry, 81 (3): 19m12891
  | Weblink |
• Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroterán-Infante N, Pichler V, Meyer B, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte H, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M (2020) On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study Transl Psychiat, 10 (2): 2
  | Weblink |
• Fabbri C, Kasper S, Kautzky A, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Uher R, Lewis C, Serretti A (2020) A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping Transl Psychiat, 10 (1): 50
  | Weblink |
• Mörkl S, Seltenreich D, Letmaier M, Bengesser S, Wurm W, Grohmann R, Bleich S, Toto S, Stübner S, Butler MI, Kasper S (2020) Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance program World J Biol Psychiatry, 21 (4): 308-316
  | Weblink |
• Baldinger-Melich P, Urquijo Castro M, Seiger R, Ruef A, Dwyer D, Kranz G, Klöbl M, Kambeitz J, Kaufmann U, Windischberger C, Kasper S, Falkai P, Lanzenberger R, Koutsouleris N (2020) Sex Matters: A Multivariate Pattern Analysis of Sex- and Gender-Related Neuroanatomical Differences in Cis- and Transgender Individuals Using Structural Magnetic Resonance Imaging Cereb. Cortex, 30 (3): 1345-1356
  | Weblink |

• Bartova L, Mitschek MMM, Kasper S (2020) Das aktuelle Verständnis der sogenannten behandlungsresistenten Depression Jatros Neurologie & Psychiatrie , 06/2020: 44-49
• Dold M, Kasper S (2020) Dose‐response relationship of selective serotonin reuptake inhibitors Acta Psychiatr Scand, 142 (6): 427-429
  | Weblink |
• McAllister-Williams R, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, Hopwood M, Javed A, Kasper S, Malhi G, Soares J, Vieta E, Young A, Papadopoulos A, Rush A (2020) The identification, assessment and management of difficult-to-treat depression: An international consensus statement J Affect Disord, 267: 264-282
  | Weblink |
• Kasper S, Bancher C, Eckert A, Förstl H, Frölich L, Hort J, Korczyn A, Kressig R, Levin O, Palomo M (2020) Management of mild cognitive impairment (MCI): The need for national and international guidelines World J Biol Psychiatry, 21 (8): 579-594
  | Weblink |
• Fountoulakis K, Moeller H, Kasper S, Tamminga C, Yamawaki S, Kahn R, Tandon R, Correll C, Javed A (2020) The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia CNS Spectr,
  | Weblink |

• Silberbauer L, James G, Spies M, Michenthaler P, Kranz GS, Kasper S, Lanzenberger R (2020) Molecular neuroimaging of the serotonergic system with PET. In: , Handbook of the Behavioral Neurobiology of Serotonin Elsevier: 175-194